Related Experiment Videos
BIII-890-CL. Boehringer Ingelheim.
1University of Alabama at Birmingham, School of Medicine, Dept of Physical Medicine and Rehabilitation, 157 Spain Rehabilitation Center, 619 19th St South, Birmingham, AL 35249-7330, USA. JMeythal@uab.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|January 17, 2003
Summary
BIII-890-CL, a sodium channel blocker, is being investigated for treating thromboembolic stroke and pain. This compound was in phase II clinical trials as of June 2002.
Area of Science:
- Pharmacology
- Neurology
- Cardiovascular Medicine
Background:
- Thromboembolic stroke poses a significant health risk.
- Sodium channels play a crucial role in neuronal and cardiac function.
- Developing novel therapeutic agents for stroke and pain management is essential.
Purpose of the Study:
- To evaluate the potential of BIII-890-CL as a treatment for thromboembolic stroke.
- To investigate the efficacy of BIII-890-CL in pain management.
- To assess the safety and tolerability of BIII-890-CL in clinical trials.
Main Methods:
- BIII-890-CL is a non-orally active sodium channel blocker.
- The compound was undergoing phase II clinical trials for thromboembolic stroke.
- Ongoing investigations included its potential application in pain treatment.
Main Results:
- Clinical trials for thromboembolic stroke were in progress as of June 2002.
- Preliminary data on efficacy and safety were being gathered.
- Further research was needed to establish therapeutic benefits.
Conclusions:
- BIII-890-CL shows promise as a potential therapeutic agent for thromboembolic stroke.
- The compound's utility in pain management warrants further investigation.
- Continued clinical development is necessary to confirm its role in patient care.